Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017839 | 0.83 | CA12 (0.40) | ALDH1A1TSHR | |
| SCHEMBL19453150 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL18526347 | 0.77 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL19201521 | 0.75 | — | — | |
| SCHEMBL11343993 | 0.74 | ALDH1A1 (0.33) | ALDH1A1TSHRTHPO | |
| SCHEMBL14710274 | 0.72 | CA4 (0.35) | ALDH1A1TSHRTHPO | |
| Dimethyl Acetylphosphonate SCHEMBL2459022 | 0.71 | — | — | |
| SCHEMBL18526575 | 0.70 | MGAM (0.39) | ALDH1A1TSHR | |
| SCHEMBL25417026 | 0.69 | — | — | |
| SCHEMBL13084170 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149990-A1 | NIRMATRELVIR ANALOGS AS 3C LIKE PROTEASE INHIBITORS FOR TREATING VIRAL INFECTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239800-A1 | PYRROLO[2,3-D]PYRIMIDIN-2-ONE ANTIMICROBIAL COMPOUNDS | RIB-X PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024028365-A1 | SUBSTITUTED PYRIDONE GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9593081-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| WO-2017019589-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150038479-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-02-05 | — | — | US | disclosed |
| US-20150038479-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-02-05 | — | — | US | disclosed |
| EP-2220046-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| WO-2012074926-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239800-A1 | PYRROLO[2,3-D]PYRIMIDIN-2-ONE ANTIMICROBIAL COMPOUNDS | LPO, MAVS, FPR2 | ALDH1A1 957/4885TSHR 3511/4885THPO 29/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | ALDH1A1 1804/4885TSHR 3455/4885THPO 3847/4885 |
| US-20150038479-A1 | ISOXAZOLE BETA-LACTAMASE INHIBITORS | ALPL, MGAM, PEPD | ALDH1A1 697/4885TSHR 4302/4885THPO 2291/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | ALDH1A1 3182/4885TSHR 80/4885THPO 977/4885 |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | ALDH1A1 2371/4885TSHR 4064/4885THPO 2480/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 2039/4885TSHR 4775/4885THPO 137/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885TSHR 4351/4885THPO 1368/4885 |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GABRA5, BCR, GABRA4 | ALDH1A1 912/4885TSHR 730/4885THPO 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.